Efficacy and safety of oral dapagliflozin in reducing proteinuria in children with proteinuric chronic kidney diseases.

All India Institute of Medical Sciences0 个研究点目标入组 0 人开始时间: 待定最近更新: 2022年5月2日

试验速览

暂无简介。

•1) Chronic kidney disease (CKD) stage 1 or 2 (eGFR greater than 60 mL/minute per 1.73 m2) 2)Nephrotic range proteinuria on two consecutive evaluations (greater than 1 g/m2 daily; greater than 40 mg/m2 /hr ) 3) On weight-appropriate dose of either an ACE-inhibitor or aldosterone receptor blocker for greater than or equal to 4 weeks, with dose not expected to change over the next 12 weeks 4) If on immunosuppression, doses not expected to change over next 12 weeks

•1) Blood pressure below 5th percentile for age, sex and height percentile
•2) Clinical or biochemical feature(s) of hypovolemia
•3) Body mass index less than -2 standard deviation scores for age and sex
•4) Diabetes mellitus or hyperglycemia
•5) Hyponatremia (serum sodium less than 135 mEq/L)
•6) Serum albumin less than 2 g/dL
•7) Hepatic transaminases (AST/ALT) greater than 3 times upper limit of normal
•8) Pancreatic injury or pancreatitis within the last 6 months
•9) Known inflammatory bowel disease; major gastrointestinal tract surgery; gastrointestinal ulcers; and/or gastrointestinal or rectal bleeding in last 6 months
•10) History of noncompliance to medical regimens or unwillingness to comply

发起方